Key events that drive cancer are influenced by a multitude of factors that still remain to be understood. One event is viral infection, which is estimated to have a role in 15% to 20% of cancers.[@R1] Cancers that have been found to be associated with viral infection include cervical,[@R1] oropharyngeal and hepatocellular carcinomas,[@R1] and some leukemias and lymphomas.[@R1] One well-known association is the role of human papillomavirus (HPV) in cervical carcinoma (CC). This relationship was discovered after isolation and identification of HPV-16 and HPV-18, now designated as high-risk mucosal HPV subtypes, in CC biopsies.[@R7] Additional studies show that infection by these and other high-risk HPV types is the primary risk factor for developing CC[@R2] such that they are identified in at least 99% of CC cases.[@R2]

In 2013, 12,340 new CC diagnoses, and 4030 CC-associated deaths are estimated.[@R12] Fortunately, early detection and preventative measures have resulted in a decrease in the mortality rate. However, our understanding of HPV integration in CC is still evolving as studies point to both the presence of HPV integration hotspots[@R13] and the absence of a correlation between HPV type and integration location.[@R13] Furthermore, despite the well-established association between HPV and CC, identification of effective therapies for patients with CC remains a challenge and emphasizes the need for additional characterization of CC tumors and further evaluation of HPV in CC.[@R15]

Given this demand, we applied next generation sequencing (NGS) to characterize somatic alterations in a live metastatic cervical squamous cell carcinoma patient and to detect and analyze HPV integration in the same sample. We performed whole-genome, exome, and RNA sequencing (RNAseq) from DNA and RNA collected from the patient's tumor biopsy specimen and peripheral blood sample. We describe here the first reported study of combined DNA and RNA sequencing as well as HPV integration and analysis in a live patient with metastatic CC.

MATERIALS AND METHODS
=====================

Please refer to the Supplemental data for detailed methods, available at <http://links.lww.com/IGC/A194>.

Ethics Statement
----------------

The patient was treated on protocols approved by the institutional review board of the Mayo Clinic. This study was conducted in accordance with the 1996 Declaration of Helsinki. Written informed consent was obtained from the patient for sequencing analyses and data release.

Patient Clinical History
------------------------

The patient's condition was diagnosed with stage IB2 squamous cell carcinoma of the cervix in June 2007. The patient underwent numerous treatments, and a metastatic lung biopsy was acquired in April 2012. This lung biopsy specimen was sent to the CRL (Clinical Reference Laboratory, Lenexa, KS) for nucleic acid isolation, and the DNA/RNA was sent to the Translational Genomics Research Institute for sequencing.

Sample Assessment
-----------------

The patient's lung biopsy specimen was preserved as fresh frozen and assessed as 100% tumor squamous carcinoma. Direct visualization of the sample was performed to estimate the tumor content and the extent of tissue heterogeneity by a board-certified pathologist.

DNA and RNA Isolation
---------------------

Blood leukocytes were isolated from the whole blood and homogenized. Genomic DNA was purified using the Qiagen AllPrep DNA spin column (Valencia, CA). Tumor DNA and RNA isolations were performed by CRL using Qiagen's AllPrep Kit.

Library Preparation, Sequencing, and Data Analysis
--------------------------------------------------

Isolated DNA and RNA were used to generate whole-genome, exome, and RNA sequencing libraries. Libraries were paired-end sequenced on the Illumina HiSeq 2000 (San Diego, CA) and analyzed after Fastq generation and alignment against the human reference genome (build 37) using the Burrows-Wheeler Alignment[@R16] for DNA sequencing data and Bowtie/Tophat[@R17] for RNA sequencing data. The dbGaP (database of Genotypes and Phenotypes) accession number for sequencing data from this study is phs000628.v1.p1.

Experimental Validation
-----------------------

To validate HPV-18 integration sites and the presence of episomal HPV-18, primers were designed upstream and downstream of 4 separate junctions. These junctions include the following: (1) E6 to long control region (LCR) (episomal HPV-18), (2) E2/E4 to chr6:4,328,779, (3) E2 to chr6:4,282,640, and (4) E1 to chr6:4,291,973. Polymerase chain reaction (PCR) was performed using each primer set on cDNA that was previously generated from tumor RNA during library construction, and PCR products were Sanger sequenced. Quantitative PCR was performed by CRL to evaluate *PIK3CA* expression with β-actin as the control gene.

RESULTS AND DISCUSSION
======================

Whole-Genome Sequencing
-----------------------

We performed shallow whole-genome sequencing (WGS) from DNA isolated from the lung biopsy specimen and whole blood sample to identify somatic copy number changes and translocations. Whole-genome sequencing metrics are listed in [Table 1](#T1){ref-type="table"}, and identified translocations and copy number changes are summarized in [Figure 1](#F1){ref-type="fig"}. Overall, we identified 21 translocations ([Table 2](#T2){ref-type="table"}) affecting at least 1 gene. Of these events, 1 affected a COSMIC (Catalogue of Somatic Mutations in Cancer)[@R19] gene, *TRIM27* (tripartite motif containing 27; *RET*). Point mutations in *TRIM27* have been identified in other cancers,[@R20] but no somatic translocations in this gene have been previously reported in CC. We additionally identified 16 genic regions demonstrating copy number variations (CNVs) encompassing 354 genes (Supplemental Digital Content Fig. S1, available at <http://links.lww.com/IGC/A194>). The 16 regions encompass 11 COSMIC genes ([Table 3](#T3){ref-type="table"}) including *PIK3CA* (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit α), *SOX2* \[SRY (sex-determining region Y)-box 2\], *IL7R* (interleukin 7 receptor), and *LIFR* (leukemia inhibitory factor receptor α). The gain identified on 5p also overlaps with *TERT* (telomerase reverse transcriptase), for which altered expression has been described in HPV-mediated CC.[@R22] The 2 regions of CNV loss (4q and 11q) did not overlap with COSMIC genes, but these events have been previously detected in CC.[@R23]

###### 

Sequencing metrics
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###### 

Identified genic intrachromosomal and interchromosomal translocations
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###### 

Identified copy number alterations affecting coding regions
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![Circos plot summarizing somatic events. A summary of all identified somatic genomic alterations is shown. Translocations are marked by purple (interchromosomal) and gray (intrachromosomal translocations) lines; for intrachromosomal translocations, the gray connecting line may appear as a single line if the joined regions lie within 2000 kb. CNVs are shown along the thick gray ring encircling the translocations (green, regions of loss; red, regions of gain; gray, no change); on the ring encircling CNVs, somatic indels (insertion/deletions) are marked by light blue tick marks and on the ring encircling the indels, somatic point mutations are marked by dark blue tick marks. Because we identified 122 nonsynonymous point mutations, splice site point mutations, and small indels, selected gene labels associated with point mutations are shown along the outermost area of the plot.](igj-24-329-g004){#F1}

Gains in CC have been reported for regions encompassing *IL7R* and *PIK3CA*. A 5p amplification encompassing *IL7R* was previously identified in a primary cervical adenocarcinoma cell line (COSMIC ID 687509). We also identified multiple gains on 3q, which include a region encompassing *PIK3CA*. The 3q amplification is considered a frequent somatic alteration in CC.[@R26] Cell line studies provide evidence that suggests that amplified *PIK3CA*, along with increased expression, may activate the PI3K/Akt pathway, lead to apoptosis inhibition, and thereby support tumor cell growth and division.[@R24] *PIK3CA* RNAseq data are detailed later. The International Cancer Genome Consortium[@R25] has also reported events in *SOX2* in CC.

Exome Sequencing
----------------

Using exome sequencing, we identified 130 nonsynonymous point mutations, splice site point mutations, and small indels (insertion deletions; [Fig. 1](#F1){ref-type="fig"}). Of these events, 3 mutations affected COSMIC genes including *WRN* (Werner syndrome, RecQ helicase-like) and *ASPSCR1* (alveolar soft part sarcoma chromosome region, candidate 1) and have not been previously reported in CC ([Table 4](#T4){ref-type="table"}). Sorting Tolerant From Intolerant (SIFT)^31^ and PolyPhen-2 (Polymorphism Phenotyping v2)^32^ were used to predict potential effects of selected point mutations on protein function ([Table 4](#T4){ref-type="table"}). We additionally performed allele frequency analysis of all identified mutations to evaluate the extent to which exome reads support a mutation (Supplemental Digital Content Table S1, available at <http://links.lww.com/IGC/A194>). Ninety-seven of 130 total mutations are supported by all exome reads at the mutation location.

###### 

Selected SNVs identified through exome sequencing
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Additional notable nonsynonymous coding mutations that were identified ([Table 4](#T4){ref-type="table"}) include *IGF1R* (insulin-like growth factor 1 receptor), *SKI* (v-ski sarcoma viral oncogene homolog (avian), and *RAD50* (RAD50 homolog \[*S. accharomyces cerevisiae*\]), and *XRCC1* (x-ray repair complementing defective repair in Chinese hamster cells 1). *IGF1R* is normally involved in initiating signaling after binding of IGF1 (insulin growth factor 1) to activate cell proliferation and inhibit apoptosis,^33^ and its overexpression has been found in both CC cell lines^34^ and specimens.^35,36^ We, however, did not identify significant *IGF1R* expression changes (corrected *P* \< 0.05) in the tumor. In addition, a recent study showed that resistance to the IGF1R inhibitor figitumamab is associated with the absence of N-linked glycosylation at N913.^37^ The mutation causing the change of asparagine to tyrosine at this position suggests that the tumor may be resistant to this inhibitor and highlights the benefit of performing WGS analyses to gain insight into therapeutic selection.

In the proto-oncogene *SKI*, we identified a coding mutation that falls in the *SMAD4* (mothers against DPP homolog 4)-binding domain. SKI acts as a corepressor of SMAD proteins and blocks the cell's ability to stop cell growth and division.[@R14]^,38^ DNA repair genes with missense mutations identified in the patient include *RAD50* and *XRCC1*. *RAD50* complexes with MRE11 and NBN (nibrin) and identifies and repairs DNA damage,^33^ whereas *XRCC1* is involved in single-stranded break repair. In *XRCC1*, we also identified an SNP (Q399R; rs25487) that was reported to be associated with persistent HPV infection.^34^ Although we do not have records of whether the sequenced patient experienced HPV persistence, this event suggests that the patient may be HPV positive.

RNA Sequencing
--------------

Commercially purchased normal cervix and normal lung RNA samples were prepared and sequenced to serve as the control(s) for differential analyses. RNA sequencing metrics are shown in [Table 1](#T1){ref-type="table"}. Tumor RNA reads were compared against normal cervix RNA reads and also compared against both normal cervix and normal lung RNA reads. Differential analysis of tumor compared with cervix led to the identification of 3468 genes showing expression changes (corrected *P* \< 0.05) of which 83 genes are listed in COSMIC. Analysis of tumor compared with both normal cervix and normal lung led to the identification of 2338 genes (corrected *P* \< 0.05), with 51 genes listed in COSMIC. Differentially expressed COSMIC genes are listed in Supplementary Table S2, available at <http://links.lww.com/IGC/A194>. In a separate analysis, we additionally identified RNA reads that support mutations identified through exome sequencing (Supplemental Digital Content Table S1). Overall, 35 of 130 mutations identified in exome data are supported by 100% of RNA reads at the respective mutation location. Supplemental data are available at <http://links.lww.com/IGC/A194>.

Consolidation of both RNAseq analyses led to the identification of 36 common differentially expressed COSMIC genes. Upon evaluation against the Cervical Cancer Gene Database,^39^ 7 of the 36 genes were found to be previously described in CC. These genes include *DEK* (DEK oncogene), *FHIT* (fragile histidine triad), *GATA3* (GATA-binding protein 3), and *KIT* (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog).

For COSMIC genes that fell in CNVs, we evaluated if these genes also demonstrated expression changes in the tumor (Supplemental Digital Content Table S3, available at <http://links.lww.com/IGC/A194>). Overall, *FANCD2* (Fanconi anemia, complementation group D2) and *SOX2*, which both fell in regions of copy number gains, showed increased expression in the tumor (corrected *P* \< 0.05) in both RNAseq comparisons. However, *PPARG* (peroxisome proliferators--activated receptor γ) and *LIFR*, which also fell in areas of gain, demonstrated decreased expression in the tumor. Low *PPARG* expression was also previously reported in CC.^36^ Given the *PIK3CA* amplification that was identified, we evaluated *PIK3CA*, which demonstrated an increased expression in the tumor but was not initially noted as it did not pass multiple testing corrections. In the tumor versus normal cervix analysis, the tumor demonstrated a log2 fold of 1.30 (*P* = 0.03), whereas in the tumor versus normal cervix and lung analysis, the tumor demonstrated a log2 fold of 1.19 (*P* = 0.126). Quantitative PCR validation confirmed *PIK3CA* overexpression in the tumor as compared against β-actin (δ Ct = 8.7; Supplemental Digital Content Table S4, available at <http://links.lww.com/IGC/A194>).

Pathway analysis was performed on each set of differential analyses using MetaCore GeneGo (corrected *P* \< 0.05). The top 10 affected pathways for each analysis are listed in Supplementary Table S5, available at <http://links.lww.com/IGC/A194>. Overall, pathways that are likely to be the most affected by identified expression changes include cell cycle processes, DNA methylation, stromal-epithelial interactions, cell adhesion, and DNA damage processes. Although these pathways are commonly affected across cancers, this information may lend additional contextual insight into CC.

HPV Detection
-------------

To determine if high-risk HPV integration had occurred in the patient, WGS reads were mapped against all 552 human viral reference sequences posted on NCBI's (National Center for Biotechnology Information) Entrez Genome Viral Genomes Resource. These 552 references include 42 HPV genomes, including those of HPV-16 and HPV-18. Results from alignment against all 42 HPV references are shown in the Supplementary Table S6, available at <http://links.lww.com/IGC/A194>. Reads aligning to HPV genomes were only aligned to HPV-16 or HPV-18. Over 19,000 tumor DNA reads were mapped to the HPV-18 genome, whereas no germline reads were mapped ([Table 1](#T1){ref-type="table"}). In the tumor, 49 reads were mapped to HPV-16, but no germline reads were mapped. Evaluation of HPV-16 reads indicated that mapped reads were discordant such that read pairs were mapped to HPV-18 and the mitochondrial genome. Confidence in these reads is low because of low mapping quality and because of 66% sequence homology between the HPV-16 and HPV-18 genomes. These analyses indicate that HPV-18 integration had occurred in the metastasis.

HPV-18 Integration Analysis
---------------------------

The HPV-18 genome consists of 6 early genes (*E1*, *E2*, *E4*, *E5*, *E6*, *E7*) and 2 late genes (*L1*, *L2*). The late genes code for viral capsid proteins, and the early genes include viral oncogenes (*E6* and *E7*) and code for proteins involved in the maintenance of transformation and viral replication. E2 codes for a transcriptional repressor that normally inhibits E6 and E7 expression. Loss of E2 expression occurs after HPV integration into the host genome and allows for E6 and E7 expression.^35,37,38^ Analysis of whole-genome and RNA data indicated that portions of HPV-18 integrated into multiple locations within a nongenic region of chromosome (chr) 6 (position 4,280,617-4,331,314; 6p25.1), which also overlaps with a region of copy number gain and is a common fragile site (FRA6B).[@R14] This finding correlates with a study that reported that 63% of HPV-18 integrations occur within common fragile sites and that significant structural events often surround integration sites.^40^ In addition, the chr6p25.1 region that we identified has been reported as an HPV-16 integration site in CC[@R14] but has not been reported for HPV-18.

The evaluation of DNA and RNA reads aligning to HPV-18 indicated that a portion of HPV-18 DNA in the tumor cells remained in the episomal form, a phenotype that has been previously reported for HPV-16 in CC.^41^ Upon investigating the 3′ end of the noncoding LCR in HPV-18, we found that approximately two thirds of DNA reads were mapped back to the E6 region to indicate that these reads were generated from episomal HPV-18 DNA. The presence of both genomic states of HPV-18 in the sequenced tumor illustrates the complexity of HPV integration and emphasizes that both spatial and temporal analyses are needed to fully understand the role of HPV in CC.

Visual inspection of DNA and RNA reads suggested that multiple integration events occurred. Because of the multicellularity of the sequenced sample, this phenotype suggests that different cells may have undergone different integration events. We assembled RNA reads from HPV-18 and discordant reads from chr6p25.1 that mapped to HPV-18 to pinpoint the major breakage events in expressed transcripts. [Figure 2](#F2){ref-type="fig"} illustrates the mapped HPV-18 RNA reads (A), assembled contigs generated from the HPV-18 RNA reads (B), and a linearized schematic of the HPV-18 genome and the chr6 region into which HPV-18 integrated (C). Overall, we assembled 155,884 paired reads to generate 20 contigs that ranged in size from 220 to 11,616 base pairs. Contigs that fully or partially aligned to HPV-18 are also shown.

![HPV-18 integration analysis. This schematic summarizes the major integration events that were detected using RNA data. Integrated Genomics Viewer was used to visualize RNA reads mapping to HPV-18 (A). A coverage track at the top of (A) illustrates HPV-18 expression levels. Orange and dark red coloring mark discordant reads that fall at breakpoints, whereas gray reads mapped without discordance. B, The figure shows the contigs assembled from the reads such that peach-colored portions of the contigs correspond to chromosome 6 sequences and blue-colored portions of the contigs correspond to HPV-18 sequences. The red contig spans the LCR and E6 regions of HPV-18 to indicate the presence of episomal DNA. The locations of identified breakpoints are shown at the top of panel B with green, purple, and pink arrows, and lineup with breakpoints identified in panel A. C, The figure shows a linearized view of the HPV-18 genome (blue) and the chromosome 6 region (peach) where HPV-18 reads were aligned. As shown in panel B and C, 3 separate events were identified (demarcated by green, purple, and pink arrows in panel B and corresponding green, purple, and pink connecting lines in panel C).](igj-24-329-g006){#F2}

We identified a contig (3B; red) that spanned HPV-18's E6 and LCR junction to provide additional evidence of the presence of HPV-18 episomes in the sequenced tumor and also demonstrated that transcription across the E6/LCR junction occurs in HPV-18 episomes. Overall, we identified 3 major breaks in the HPV-18 genome ([Figs. 2](#F2){ref-type="fig"}B-C). The breaks shown in [Figure 2](#F2){ref-type="fig"}C colored purple and pink may represent different points (in different cells) where the circular viral genome opened during integration as an early event in HPV-18 integration is the disruption of the *E2* gene to allow for genome linearization. A caveat with these analyses is that the contigs are a representation of the most commonly occurring events. Additional events that are less common in the cells of the sequenced biopsy may not be captured using this approach.

Transcriptomic Analysis of *HPV-18* Gene Expression
---------------------------------------------------

We additionally used the tumor HPV-18 reads to evaluate expression of *HPV-18* genes. Because of the absence of a control dataset for the *HPV-18* genes, we evaluated the number of reads that were acquired for each gene to determine the level of expression (Supplemental Digital Content Table S7, available at <http://links.lww.com/IGC/A194>). We identified 4103 reads mapping to E2, but no expression of integrated E2 regions, as is expected because integration disrupts E2 to subsequently allow for increased expression of E6 and E7, which we also identified in the patient's tumor. We also identified expression of E5---loss of E5 expression is associated with HPV integration^42^ and thus correlates with the presence of HPV-18 episomes in the biopsied tumor cells. In conjunction with high levels of E6 and E7 expression (3774 and 2922 reads, respectively) and integration of both genes into chr6, we see over 550X mapped reads in the chromosome 6 region affected by HPV-18 integration. This phenotype is likely the result of viral promotion of E6 and E7 expression, which subsequently promotes expression of the intronic chromosome 6 regions situated at the 3′ end of the integrated viral oncogenes.

After HPV integration, HPV proteins acquire control of host cellular pathways. We thus evaluated expression changes of genes whose products are affected by HPV proteins. These genes include *TP53* (tumor protein p53), *WAF1/CDKN1A* (p21; cycle-dependent kinase inhibitor 1A), *RB1* (retinoblastoma 1), *CCNE2* (cyclin E2), *E2F1* (E2F transcription factor 1), *CDKN2A* (cyclin-dependent kinase inhibitor 2A), *BRD4* (bromodomain containing 4), and *CDC25A* (cell division cycle 25A; Supplemental Digital Content Table S8, available at <http://links.lww.com/IGC/A194>). These genes have roles in 2 key tumor suppressor pathways affected by HPV-18's *E6* and *E7* genes. Overall, we identified increased expression of *TP53*, *CCNE2*, *E2F1*, *CDKN2A*, and *CDC25A* (corrected *P* \< 0.05). HPV-18's E6 protein targets and inhibits p53 such that the up-regulated *TP53* expression identified in the tumor may represent a compensatory response. Furthermore, p53 is activated by p14/CDKNA2A such that up-regulated expression of *CDKN2A* may also represent a response to inhibition of p53's functions. HPV-18's E7 protein also degrades RB1 and inhibits the RB1 tumor suppressor pathway causing abnormal gene expression normally controlled by E2F, CDK2 complex activation, and increasing CDC25 protein. The significantly up-regulated expression of *CCNE2*, *E2F1*, and *CDC25A* that we identified thus correlate with RB1 pathway inhibition that would result from E7 expression.

HPV-18 Integration Validation
-----------------------------

To validate the presence of the 4 identified junctions resulting from HPV-18 integration and the presence of episomal HPV-18 DNA, we performed PCR of regions spanning the 4 junctions on cDNA generated from tumor RNA. These junctions include HPV-18 LCR-E6 (found in episomal forms of HPV-18), E1-chr6:4,291,973, E2-chr6:4,282,640, and E2/E4-chr6:4,328,779. PCR products were Sanger sequenced, and resulting chromatograms confirmed the presence of the 4 junctions (Supplemental Digital Content Figure S2, available at <http://links.lww.com/IGC/A194>).

CONCLUSIONS
===========

In this study, we used NGS to characterize somatic alterations in a patient with CC as well as to identify and analyze HPV integration. Although combined DNA and RNA sequencing has been performed for other cancers, this study is the first to apply this approach to a patient with CC and to concurrently analyze HPV integration in the same sequencing data. Before sequencing, the patient's HPV status was not known but using NGS, we determined that HPV-18 integration had occurred in the patient's tumor and subsequently identified a novel integration site on chr6p25.1. We also found that although some tumor cells in the biopsy garnered episomal HPV-18, other cells had undergone HPV-18 integration. Although this phenotype has been reported for HPV-16 in CC, this finding reiterates the need to consider both spatial and temporal analyses to fully understand the role of HPV in CC. The approach used in this study is relevant not only to HPV-associated carcinomas but also to other malignancies involving viral infection. Furthermore, using NGS to simultaneously characterize a tumor genome and to analyze HPV integration is relevant for CC because HPV integration is not the sole driving event in CC as additional debilitating events are required for carcinogenesis.^43^ As we continue to sequence CC tumors, we set the foundation for improving our molecular knowledge of HPV, CC, and HPV in CC.
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